

CITATION REPORT

List of articles citing

The secretases: enzymes with therapeutic potential in Alzheimer disease

DOI: 10.1038/nrneurol.2009.218

Nature Reviews Neurology, 2010, 6, 99-107.

Source: <https://exaly.com/paper-pdf/49682145/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
652	Geriatric medicine, Japanese Alzheimer's disease neuroimaging initiative and biomarker development. 2010 , 221, 87-95		8
651	Do amyloid associated factors co-deposit with A β in mouse models for Alzheimer's disease?. <i>Journal of Alzheimer's Disease</i> , 2010 , 22, 345-55	4.3	13
650	Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease. 2010 , 119, 523-41		267
649	EGCG functions through estrogen receptor-mediated activation of ADAM10 in the promotion of non-amyloidogenic processing of APP. 2010 , 584, 4259-67		61
648	Novel huprine derivatives with inhibitory activity toward A β amyloid aggregation and formation as disease-modifying anti-Alzheimer drug candidates. 2010 , 5, 1855-70		46
647	Current awareness in geriatric psychiatry. 2010 , 25, i-viii		
646	Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model. 2010 , 20, 6231-6		39
645	BACE-1 elevation in aged monkey and Alzheimer's disease human cerebral cortex occurs around the vasculature in partnership with multisystem axon terminal pathogenesis and A β amyloid accumulation. 2010 , 32, 1223-38		46
644	Dysfunction of G protein-coupled receptor kinases in Alzheimer's disease. 2010 , 10, 1667-78		24
643	Alzheimer's disease: a general introduction and pathomechanism. <i>Journal of Alzheimer's Disease</i> , 2010 , 22 Suppl 3, 5-19	4.3	116
642	Amyloid beta 42 peptide (A β 42)-lowering compounds directly bind to A β and interfere with amyloid precursor protein (APP) transmembrane dimerization. 2010 , 107, 14597-602		92
641	Participation of transmembrane domain 1 of presenilin 1 in the catalytic pore structure of the BACE-1. 2010 , 30, 15943-50		50
640	GRK5 deficiency accelerates A β -amyloid accumulation in Tg2576 mice via impaired cholinergic activity. 2010 , 285, 41541-8		25
639	Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants. 2010 , 3, 3040-3100		29
638	MPlot--a server to analyze and visualize tertiary structure contacts and geometrical features of helical membrane proteins. 2010 , 38, W602-8		3
637	Alzheimer's disease: the quest to understand complexity. <i>Journal of Alzheimer's Disease</i> , 2010 , 21, 373-83.3	4.3	21
636	Phospholipase d2 ablation ameliorates Alzheimer's disease-linked synaptic dysfunction and cognitive deficits. 2010 , 30, 16419-28		140

635	Spectroscopic studies of GSK3{beta} phosphorylation of the neuronal tau protein and its interaction with the N-terminal domain of apolipoprotein E. 2010 , 285, 33435-33444	52
634	Ectdomain shedding and regulated intracellular proteolysis in the central nervous system. 2010 , 10, 337-59	15
633	Epstein-Barr virus: novel patented therapeutics. 2010 , 20, 807-18	6
632	Amyloid A β cut from APP by β secretase BACE1 and β secretase, induces apoptosis via opening type-1 porin/VDAC in cell membranes of hypometabolic cells-A basic model for the induction of apoptosis!?. 2010 , 101, 301-3	14
631	Novel research horizons for presenilins and β secretases in cell biology and disease. 2010 , 26, 235-60	203
630	Selectivity to amyloid- β precursor protein cleavage provides hope against Alzheimer's. 2011 , 3, 7	2
629	Alzheimer's therapy: a BACE in the hand?. 2011 , 17, 932-3	7
628	Discovery of BIIB042, a Potent, Selective, and Orally Bioavailable β secretase Modulator. 2011 , 2, 786-91	24
627	Reward and autoreceptors. 2011 , 14, 950	
626	What makes a prognostic biomarker in CNS diseases: strategies for targeted biomarker discovery? Part 2: chronic progressive and relapsing disease. 2011 , 5, 393-410	3
625	Biogenesis of Melanosomes. 2011 , 247-294	4
624	Regenerative medicine in multiple sclerosis: identifying pharmacological targets of adult neural stem cell differentiation. 2011 , 59, 329-32	33
623	Neuroprotective therapeutics for Alzheimer's disease: progress and prospects. 2011 , 32, 141-7	98
622	Presenilin mouse and zebrafish models for dementia: focus on neurogenesis. 2011 , 93, 149-64	30
621	The A β oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. 2011 , 96, 529-43	314
620	β secretase modulators as potential disease modifying anti-Alzheimer's drugs. 2011 , 54, 669-98	134
619	Protein kinase C-regulated A β production and clearance. 2011 , 2011, 857368	19
618	Contribution of Multivesicular Bodies to the Prion-Like Propagation of Lesions in Alzheimer's Disease. 2011 ,	

617	Future targeted disease modifying drugs for Alzheimer's disease. 2011 , 6, 65-76	
616	BACE inhibitors as potential drugs for the treatment of Alzheimer's disease: focus on bioactivity. 2011 , 6, 91-106	49
615	Consensus document on European brain research. 2011 , 33, 768-818	19
614	Presenilin-1 but not amyloid precursor protein mutations present in mouse models of Alzheimer's disease attenuate the response of cultured cells to β secretase modulators regardless of their potency and structure. 2011 , 116, 385-95	40
613	The -980C/G polymorphism in APH-1A promoter confers risk of Alzheimer's disease. 2011 , 10, 711-9	8
612	Intramembrane proteolysis in regulated protein trafficking. 2011 , 12, 1109-18	38
611	The role of G protein-coupled receptors in the pathology of Alzheimer's disease. 2011 , 12, 73-87	198
610	Cancer: The flipside of Notch. 2011 , 473, 159-60	11
609	Neurotherapeutic applications of nanoparticles in Alzheimer's disease. 2011 , 152, 208-31	144
608	Data-driven modeling of Alzheimer disease pathogenesis. 2011 , 290, 60-72	28
607	Carbazole-containing arylcarboxamides as BACE1 inhibitors. 2011 , 21, 6657-61	17
606	Rational design and synthesis of aminopiperazinones as β secretase (BACE) inhibitors. 2011 , 21, 7255-60	40
605	From fragment screening to in vivo efficacy: optimization of a series of 2-aminoquinolines as potent inhibitors of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1). 2011 , 54, 5836-57	112
604	New pathway links β secretase to inflammation and memory while sparing notch. 2011 , 69, 5-7	2
603	Design, synthesis, and testing of an 6-O-linked series of benzimidazole based inhibitors of CDK5/p25. 2011 , 19, 359-73	16
602	Quinazolinones as β secretase modulators. 2011 , 21, 773-6	18
601	Triazoles as β secretase modulators. 2011 , 21, 4083-7	15
600	Site-specific characterization of threonine, serine, and tyrosine glycosylations of amyloid precursor protein/amyloid beta-peptides in human cerebrospinal fluid. 2011 , 108, 11848-53	165

599	Therapeutic targets in Alzheimer's disease and related tauopathies. 2011 , 98, 47-83	8
598	Alzheimer's dementia begins as a disease of small blood vessels, damaged by oxidative-induced inflammation and dysregulated amyloid metabolism: implications for early detection and therapy. 2011 , 25, 5-13	176
597	Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy. 2011 , 31, 4124-36	81
596	DC2 and keratinocyte-associated protein 2 (KCP2), subunits of the oligosaccharyltransferase complex, are regulators of the gamma-secretase-directed processing of amyloid precursor protein (APP). 2011 , 286, 31080-91	11
595	BACE1 activity is modulated by cell-associated sphingosine-1-phosphate. 2011 , 31, 6850-7	138
594	An overlooked neurotoxic species in Alzheimer's disease. 2011 , 14, 949-50	12
593	Phenylpiperidine-type B-secretase modulators target the transmembrane domain 1 of presenilin 1. 2011 , 30, 4815-24	100
592	A brief history of APP secretases, their substrates and their functions. 2012 , 9, 138-9	1
591	The mechanism of B-secretase dysfunction in familial Alzheimer disease. 2012 , 31, 2261-74	357
590	Calsyntenin-1 mediates axonal transport of the amyloid precursor protein and regulates A β production. 2012 , 21, 2845-54	77
589	No association between ADCYAP1R1 and post-traumatic stress disorder in two independent samples. 2012 , 17, 239-41	44
588	Phosphorylation of amyloid- β peptide at serine 8 attenuates its clearance via insulin-degrading and angiotensin-converting enzymes. 2012 , 287, 8641-51	49
587	Extracting β amyloid from Alzheimer's disease. 2012 , 109, 3199-200	12
586	Retention in endoplasmic reticulum 1 (RER1) modulates amyloid- β (A β) production by altering trafficking of B-secretase and amyloid precursor protein (APP). 2012 , 287, 40629-40	24
585	Role of genes linked to sporadic Alzheimer's disease risk in the production of β amyloid peptides. 2012 , 109, 15307-11	47
584	Alzheimer's therapeutics: translation of preclinical science to clinical drug development. 2012 , 37, 261-77	34
583	The neural cell adhesion molecules L1 and CHL1 are cleaved by BACE1 protease in vivo. 2012 , 287, 25927-40	130
582	Formononetin protects neurons against hypoxia-induced cytotoxicity through upregulation of ADAM10 and sAPP β <i>Journal of Alzheimer's Disease</i> , 2012 , 28, 795-808	4-3 37

581	A canine model to evaluate efficacy and safety of β secretase inhibitors and modulators. <i>Journal of Alzheimer's Disease</i> , 2012 , 28, 809-22	4-3	16
580	Synthesis of novel tetrahydro-1H-pyrazolo[4,3-c]pyridines via intramolecular nitrilimine cycloaddition. 2012 , 60, 1063-6		6
579	Design and preparation of a potent series of hydroxyethylamine containing β secretase inhibitors that demonstrate robust reduction of central β amyloid. 2012 , 55, 9009-24		54
578	A practical entry to β aryl- β alkyl amino alcohols: application to the synthesis of a potent BACE1 inhibitor. 2012 , 10, 6758-66		10
577	Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease. 2012 , 287, 41245-57		95
576	Activation of PPAR γ prevents endothelial dysfunction induced by overexpression of amyloid- β precursor protein. 2012 , 96, 504-12		23
575	A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects. 2012 , 51, 681-93		36
574	Protein phosphatases and Alzheimer's disease. 2012 , 106, 343-79		68
573	BACE1 in central nervous system myelination revisited. 2012 , 17, 237-9		12
572	A Potent and Orally Efficacious, Hydroxyethylamine-Based Inhibitor of β Secretase. 2012 , 3, 886-91		26
571	"It Ain't Over 'til It's Over" (a) -The Search for Treatments and Cures for Alzheimer's Disease. 2012 , 3, 862-6		11
570	Substance P activates ADAM9 mRNA expression and induces β secretase-mediated amyloid precursor protein cleavage. 2012 , 62, 1954-63		17
569	Preventing Alzheimer's disease. 2012 , 337, 1488-92		280
568	New tacrine-4-oxo-4H-chromene hybrids as multifunctional agents for the treatment of Alzheimer's disease, with cholinergic, antioxidant, and β amyloid-reducing properties. 2012 , 55, 1303-17		211
567	Presenilin-1 L166P mutant human pluripotent stem cell-derived neurons exhibit partial loss of β secretase activity in endogenous amyloid- β generation. 2012 , 180, 2404-16		84
566	Synthesis and structure-activity relationship studies of 1,3-disubstituted 2-propanols as BACE-1 inhibitors. 2012 , 22, 4740-4		13
565	Alzheimer mechanisms and therapeutic strategies. 2012 , 148, 1204-22		1278
564	β Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment. 2012 , 4, 980-91		109

563	Linking amyloid- β and tau: amyloid- β -induced synaptic dysfunction via local wreckage of the neuronal cytoskeleton. 2012 , 10, 64-72		69
562	Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?. 2012 , 3, 857-72		108
561	Alzheimer's disease: A protective mutation. 2012 , 488, 38-9		16
560	What are the prospects of slowing the progression of Alzheimer's disease?. 2012 , 17, 1157-9		3
559	Huprine-tacrine heterodimers as anti-amyloidogenic compounds of potential interest against Alzheimer's and prion diseases. 2012 , 55, 661-9		74
558	Neutralization of the β -secretase activity by monoclonal antibody against extracellular domain of nicastrin. 2012 , 31, 787-798		57
557	Alzheimer's disease-related loss of Pin1 function influences the intracellular localization and the processing of APP. <i>Journal of Alzheimer's Disease</i> , 2012 , 30, 277-97	4-3	28
556	Identification of BACE2 as an avid β -amyloid-degrading protease. <i>Molecular Neurodegeneration</i> , 2012 , 7, 46	19	41
555	Inhibition of β -secretase worsens memory deficits in a genetically congruous mouse model of Danish dementia. <i>Molecular Neurodegeneration</i> , 2012 , 7, 19	19	68
554	Overlapping profiles of APPeptides in the Alzheimer's disease and pathological aging brains. 2012 , 4, 18		81
553	Alzheimer's-related peptide amyloid- β plays a conserved role in angiogenesis. 2012 , 7, e39598		31
552	Integrating experimentation and quantitative modeling to enhance discovery of Beta amyloid lowering therapeutics for Alzheimer's disease. <i>Frontiers in Pharmacology</i> , 2012 , 3, 177	5.6	5
551	β -Secretase Modulators: Can We Combine Potency with Safety?. 2012 , 2012, 295207		23
550	Genomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics. 2012 , 2012, 518901		38
549	Purification and aggregation of the amyloid precursor protein intracellular domain. 2012 , e4204		
548	Nuclear factor- κ B regulates APP and β -secretases differently at physiological and supraphysiological APP concentrations. 2012 , 287, 24573-84		87
547	Cytoprotective effects of hesperetin and hesperidin against amyloid β -induced impairment of glucose transport through downregulation of neuronal autophagy. 2012 , 56, 601-9		61
546	β -but not β -secretase proteolysis of APP causes synaptic and memory deficits in a mouse model of dementia. 2012 , 4, 171-9		103

545	Huprine derivatives as sub-nanomolar human acetylcholinesterase inhibitors: from rational design to validation by X-ray crystallography. 2012 , 7, 400-5	27
544	Regulation of BACE1 by miR-29a/b in a cellular model of Spinocerebellar Ataxia 17. 2012 , 9, 891-9	35
543	Small-molecule BACE1 inhibitors: a patent literature review (2006 - 2011). 2012 , 22, 511-40	74
542	NSAIDs in the treatment and/or prevention of neurological disorders. 2012 , 20, 159-67	6
541	Physiological functions of the amyloid precursor protein secretases ADAM10, BACE1, and presenilin. 2012 , 217, 331-41	41
540	Structure based design of iminohydantoin BACE1 inhibitors: identification of an orally available, centrally active BACE1 inhibitor. 2012 , 22, 2444-9	98
539	Design and synthesis of dihydrobenzofuran amides as orally bioavailable, centrally active β secretase modulators. 2012 , 22, 2906-11	27
538	Triazoloamides as potent β secretase modulators with reduced hERG liability. 2012 , 22, 3140-6	17
537	Membrane trafficking pathways in Alzheimer's disease. 2012 , 13, 759-70	142
536	Sulfonimidamides as sulfonamides bioisosteres: rational evaluation through synthetic, in vitro, and in vivo studies with β secretase inhibitors. 2012 , 7, 396-9	55
535	Microbial and fungal protease inhibitors--current and potential applications. 2012 , 93, 1351-75	92
534	Competition between homodimerization and cholesterol binding to the C99 domain of the amyloid precursor protein. 2013 , 52, 5051-64	84
533	Phosphatidylinositol-3-phosphate regulates sorting and processing of amyloid precursor protein through the endosomal system. 2013 , 4, 2250	147
532	Retrospective molecular docking study of WY-25105 ligand to β secretase and bias of the three-dimensional structure flexibility. 2013 , 19, 2971-9	5
531	Potential repurposing of oncology drugs for the treatment of Alzheimer's disease. 2013 , 11, 82	11
530	Redundancy and divergence in the amyloid precursor protein family. 2013 , 587, 2036-45	57
529	Olfactory functions scale with circuit restoration in a rapidly reversible Alzheimer's disease model. 2013 , 33, 12208-17	27
528	Brain endogenous estrogen levels determine responses to estrogen replacement therapy via regulation of BACE1 and NEP in female Alzheimer's transgenic mice. 2013 , 47, 857-67	55

527	BACE1 as a therapeutic target in Alzheimer's disease: rationale and current status. 2013 , 30, 755-64	31
526	The Alzheimer's β -secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques. 2013 , 126, 329-52	153
525	Mitochondrial impairment induced by 3-nitropropionic acid is enhanced by endogenous metalloprotease activity inhibition in cultured rat striatal neurons. 2013 , 546, 16-20	2
524	Identification of BACE1 inhibitors from Panax ginseng saponins-An Insilco approach. 2013 , 43, 1037-44	41
523	A fast growing spectrum of biological functions of β -secretase in development and disease. 2013 , 1828, 2815-27	93
522	Mercaptoacetamide-based class II HDAC inhibitor lowers A β levels and improves learning and memory in a mouse model of Alzheimer's disease. 2013 , 239, 192-201	100
521	An overview of the diverse roles of G-protein coupled receptors (GPCRs) in the pathophysiology of various human diseases. 2013 , 31, 1676-94	119
520	Pharmacologic inhibition of ROCK2 suppresses amyloid- β production in an Alzheimer's disease mouse model. 2013 , 33, 19086-98	98
519	PDK1 decreases TACE-mediated β -secretase activity and promotes disease progression in prion and Alzheimer's diseases. 2013 , 19, 1124-31	78
518	Regulation of distinct pools of amyloid β protein by multiple cellular proteases. 2013 , 5, 37	15
517	New cylindrical peptide assemblies defined by extended parallel β -sheets. 2013 , 11, 425-9	24
516	Critique of the use of fluorescence-based reporters in Escherichia coli as a screening tool for the identification of peptide inhibitors of A β 2 aggregation. 2013 , 19, 74-83	4
515	Presenilin-1 adopts pathogenic conformation in normal aging and in sporadic Alzheimer's disease. 2013 , 125, 187-99	58
514	ADAM10 prodomain mutations cause late-onset Alzheimer's disease: not just the latest FAD. 2013 , 80, 250-3	22
513	Chronic 5-HT4 receptor activation decreases A β production and deposition in hAPP/PS1 mice. 2013 , 34, 1779-89	37
512	Triazolopyrimidinones as β -secretase modulators: structure-activity relationship, modulator profile, and in vivo profiling. 2013 , 4, 422	9
511	Effect of helical conformation and side chain structure on β -secretase inhibition by β -peptide foldamers: insight into substrate recognition. 2013 , 56, 1443-54	22
510	Neurosteroids as regenerative agents in the brain: therapeutic implications. 2013 , 9, 241-50	114

509	Spirocyclic β -site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors: from hit to lowering of cerebrospinal fluid (CSF) amyloid β in a higher species. 2013 , 56, 3379-403	43
508	Exploring the Structures of β -Amyloid Oligomers in Aqueous Solution Using Coarse-Grained Protein Models. 2013 , 283-303	
507	Dual cleavage of neuregulin 1 type III by BACE1 and ADAM17 liberates its EGF-like domain and allows paracrine signaling. 2013 , 33, 7856-69	93
506	Development and therapeutic implications of selective histone deacetylase 6 inhibitors. 2013 , 56, 6297-313	95
505	Problems During Aging (Alzheimer β and Others). 2013 , 2953-2969	
504	Adenosine Receptors and Alzheimer β Disease. 2013 , 385-407	2
503	Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and	24
502	(R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007): metabolically stable β -secretase inhibitors that selectively inhibit the production of A-ring modification of SCH 900229 and related chromene sulfone β -secretase inhibitors. 2013 , 23, 850-3	1
501	Brain regional correlation of amyloid- β with synapses and apolipoprotein E in non-demented individuals: potential mechanisms underlying regional vulnerability to amyloid- β accumulation. 2013 , 125, 535-47	42
500	The substrate degradome of meprin metalloproteases reveals an unexpected proteolytic link between meprin β and ADAM10. 2013 , 70, 309-33	100
499	Integrated One-Against-One Classifiers as Tools for Virtual Screening of Compound Databases: A Case Study with CNS Inhibitors. 2013 , 32, 742-53	6
498	β -Secretase inhibitors and modulators. 2013 , 1828, 2898-907	190
497	The role of s-nitrosylation and s-glutathionylation of protein disulphide isomerase in protein misfolding and neurodegeneration. 2013 , 2013, 797914	44
496	Exploring amyloid aggregates with coarse-grained protein simulations. 2013 , 1535, 6001	
495	Loss of c-Jun N-terminal kinase-interacting protein-1 does not affect axonal transport of the amyloid precursor protein or A β production. 2013 , 22, 4646-52	17
494	Amyloid- β increases capillary bed density in the adult zebrafish retina. 2013 , 54, 1516-21	17
493	Mechanism of amyloid β protein dimerization determined using single-molecule AFM force spectroscopy. 2013 , 3, 2880	58
492	Mechanisms that lessen benefits of β -secretase reduction in a mouse model of Alzheimer's disease. 2013 , 3, e284	24

491	1,3-Oxazines as BACE1 and/or BACE2 inhibitors: a patent evaluation (WO2012156284). 2013 , 23, 1069-73		6
490	BACE2 processes PMEL to form the melanosome amyloid matrix in pigment cells. 2013 , 110, 10658-63		116
489	βSecretase modulator (GSM) photoaffinity probes reveal distinct allosteric binding sites on presenilin. 2013 , 288, 9710-9720		85
488	Aftins increase amyloid-β ₂ , lower amyloid-β ₈ , and do not alter amyloid-β ₀ extracellular production in vitro: toward a chemical model of Alzheimer's disease?. <i>Journal of Alzheimer's Disease</i> , 2013 , 35, 107-20	4.3	13
487	Effect of alanine replacement of l17 and f19 on the aggregation and neurotoxicity of arctic-type aβ ₀ . 2013 , 8, e61874		7
486	Exploring the contribution of estrogen to amyloid-Beta regulation: a novel multifactorial computational modeling approach. <i>Frontiers in Pharmacology</i> , 2013 , 4, 16	5.6	31
485	Cellular and animal models for high-throughput screening of therapeutic agents for the treatment of the diseases of the elderly in general and Alzheimer's disease in particular(I). <i>Frontiers in Pharmacology</i> , 2013 , 4, 59	5.6	4
484	Potential Therapeutic Strategies to Prevent the Progression of Alzheimer to Disease States. 2013 ,		2
483	Extracellular proteolysis of apolipoprotein E (apoE) by secreted serine neuronal protease. 2014 , 9, e93120		26
482	Genetic inhibition of phosphorylation of the translation initiation factor eIF2β does not block Aβ dependent elevation of BACE1 and APP levels or reduce amyloid pathology in a mouse model of Alzheimer's disease. 2014 , 9, e101643		29
481	Effect of the CALHM1 G330D and R154H human variants on the control of cytosolic Ca ²⁺ and Aβ levels. 2014 , 9, e112484		9
480	Aβ degradation-the inside story. 2014 , 6, 229		5
479	Physiological Role of Amyloid Beta in Neural Cells: The Cellular Trophic Activity. 2014 ,		19
478	Molecular mechanism of intramembrane proteolysis by βSecretase. 2014 , 156, 195-201		44
477	Sphingosine-1-phosphate: boon and bane for the brain. 2014 , 34, 148-57		38
476	βSecretase processing and effects of βSecretase inhibitors and modulators on long Aβ peptides in cells. 2014 , 289, 3276-87		21
475	Mechanisms of action of phytochemicals from medicinal herbs in the treatment of Alzheimer's disease. 2014 , 80, 1249-58		63
474	Assay suitability for natural product screening: searching for leads to fight Alzheimer's disease. 2014 , 80, 1200-9		4

473	Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects. 2014 , 130, 4-28	232
472	Small molecules that inhibit Notch signaling. 2014 , 1187, 311-22	17
471	CSF beta-amyloid levels are altered in narcolepsy: a link with the inflammatory hypothesis?. 2014 , 23, 420-4	34
470	Anilino-triazoles as potent gamma secretase modulators. 2014 , 24, 5805-5813	14
469	8-Tetrahydropyran-2-yl chromans: highly selective beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors. 2014 , 57, 10112-29	15
468	Altered CpG methylation in sporadic Alzheimer's disease is associated with APP and MAPT dysregulation. 2014 , 23, 648-56	96
467	Protein misfolding, congophilia, oligomerization, and defective amyloid processing in preeclampsia. 2014 , 6, 245ra92	122
466	Conformational targeting of intracellular A β oligomers demonstrates their pathological oligomerization inside the endoplasmic reticulum. 2014 , 5, 3867	42
465	BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. 2014 , 6, 89	279
464	A Novel Presenilin 1 Mutation in Early-Onset Alzheimer's Disease With Prominent Frontal Features. 2014 , 29, 433-5	10
463	Combined treatment with a BACE inhibitor and anti-A β antibody gantenerumab enhances amyloid reduction in APPLondon mice. 2014 , 34, 11621-30	69
462	Critical analysis of the use of β -site amyloid precursor protein-cleaving enzyme 1 inhibitors in the treatment of Alzheimer's disease. 2014 , 4, 1-19	3
461	Membrane lipid modifications and therapeutic effects mediated by hydroxydocosa-hexaenoic acid on Alzheimer's disease. 2014 , 1838, 1680-92	37
460	Amyloid- β diurnal pattern: possible role of sleep in Alzheimer's disease pathogenesis. 2014 , 35 Suppl 2, S29-34	96
459	FLZ inhibited β -secretase selectively and decreased A β mitochondrial production in APP-SH-SY5Y cells. 2014 , 387, 75-85	7
458	Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer's disease. 2014 , 88, 617-30	32
457	Alzheimer's disease, enzyme targets and drug discovery struggles: from natural products to drug prototypes. 2014 , 15, 116-45	98
456	The amyloid state and its association with protein misfolding diseases. 2014 , 15, 384-96	1481

455	Metabolism and mis-metabolism of the neuropathological signature protein TDP-43. 2014 , 127, 3024-38	64
454	Synthesis, characterization, and PK/PD studies of a series of spirocyclic pyranochromene BACE1 inhibitors. 2014 , 24, 2477-80	12
453	Design, synthesis, and pharmacological evaluation of a novel series of pyridopyrazine-1,6-dione β -secretase modulators. 2014 , 57, 1046-62	25
452	Endothelial nitric oxide: protector of a healthy mind. 2014 , 35, 888-94	148
451	New insights into the role of glycogen synthase kinase-3 in Alzheimer's disease. 2014 , 18, 69-77	36
450	Discovery of 7-tetrahydropyran-2-yl chromans: site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors that reduce amyloid β -protein (A β) in the central nervous system. 2014 , 57, 878-902	32
449	A cellular model of amyloid precursor protein processing and amyloid- β peptide production. 2014 , 223, 114-22	15
448	Alzheimer's Disease. 2014 , 889-920	1
447	Quantum dot-based concentric FRET configuration for the parallel detection of protease activity and concentration. 2014 , 86, 11181-8	40
446	Inhibiting ACAT1/SOAT1 in microglia stimulates autophagy-mediated lysosomal proteolysis and increases A β -42 clearance. 2014 , 34, 14484-501	70
445	Amyloid precursor protein and neural development. 2014 , 141, 2543-8	99
444	Combating neurodegenerative disease with chemical probes and model systems. 2014 , 10, 911-20	37
443	Real-time probing of β -amyloid self-assembly and inhibition using fluorescence self-quenching between neighbouring dyes. 2014 , 10, 34-44	27
442	F-box only protein 2 (Fbxo2) regulates amyloid precursor protein levels and processing. 2014 , 289, 7038-7048	26
441	Pharmacogenomics of Alzheimer's disease: novel therapeutic strategies for drug development. 2014 , 1175, 323-556	50
440	Complex relationships between substrate sequence and sensitivity to alterations in β -secretase processivity induced by β -secretase modulators. 2014 , 53, 1947-57	14
439	Notch Signaling. 2014 ,	2
438	Peptides containing β -amino acid patterns: challenges and successes in medicinal chemistry. 2014 , 57, 9718-39	171

437	From epidemiology to pathophysiology: what about caffeine in Alzheimer's disease?. 2014 , 42, 587-92	34
436	Surgical menopause enhances hippocampal amyloidogenesis following global cerebral ischemia. 2014 , 3, 206-216	1
435	Personalized Medicine of Alzheimer's Disease. 2014 , 563-615	1
434	Creation of Novel Cores for β -Secretase (BACE-1) Inhibitors: A Multiparameter Lead Generation Strategy. 2014 , 5, 440-5	11
433	Exendin-4 promotes the membrane trafficking of the AMPA receptor GluR1 subunit and ADAM10 in the mouse neocortex. 2014 , 190-191, 1-11	24
432	Targeting the β -Secretase BACE1 for Alzheimer's disease therapy. 2014 , 13, 319-29	438
431	Applications of copper-catalyzed click chemistry in activity-based protein profiling. 2014 , 19, 1378-93	57
430	Early Intervention in Older Adults A Focus on Alzheimer's Dementia. 2014 , 103-115	
429	Effects and possible mechanisms of action of acacetin on the behavior and eye morphology of <i>Drosophila</i> models of Alzheimer's disease. 2015 , 5, 16127	30
428	Generation of Rabbit Monoclonal Antibody to Amyloid- β 8 (A β 8): Increased Plasma A β 8 Levels in Down Syndrome. <i>Journal of Alzheimer's Disease</i> , 2015 , 46, 1021-32	4-3 3
427	Targeting the β -Secretase interaction reduces β -amyloid generation and ameliorates Alzheimer's disease-related pathogenesis. 2015 , 1, 15021	25
426	Brain toxicity and inflammation induced in vivo in mice by the amyloid- β 42 inducer aftin-4, a roscovitine derivative. <i>Journal of Alzheimer's Disease</i> , 2015 , 44, 507-24	4-3 8
425	Alzheimer's Disease. 2015 , 1-21	
424	Neuronal ADAM10 Promotes Outgrowth of Small-Caliber Myelinated Axons in the Peripheral Nervous System. 2015 , 74, 1077-85	6
423	Amyloid β -protein oligomers upregulate the β -Secretase, BACE1, through a post-translational mechanism involving its altered subcellular distribution in neurons. 2015 , 8, 73	28
422	Supramolekulare Assays zur Lokalisation von Enzymaktivit durch Verdrigungs-induzierte nderungen in der Magnetisierungstransfer-NMR-Spektroskopie mit hyperpolarisiertem ^{129}Xe . 2015 , 127, 13645-13648	11
421	Supramolecular Assays for Mapping Enzyme Activity by Displacement-Triggered Change in Hyperpolarized (^{129}Xe) Magnetization Transfer NMR Spectroscopy. 2015 , 54, 13444-7	50
420	Beneficial effects of the β -Secretase inhibitor GRL-8234 in 5XFAD Alzheimer's transgenic mice lessen during disease progression. 2015 , 12, 13-21	16

419	Neuroinflammation in Alzheimer's disease. 2015 , 11, 243-56	164
418	Amyloid beta-protein and lipid rafts: focused on biogenesis and catabolism. 2015 , 20, 314-24	11
417	The Maze of APP Processing in Alzheimer's Disease: Where Did We Go Wrong in Reasoning?. 2015 , 9, 186	22
416	Purification and Characterization of Recombinant N-Terminally Pyroglutamate-Modified Amyloid- β Variants and Structural Analysis by Solution NMR Spectroscopy. 2015 , 10, e0139710	16
415	Structural Analysis and Aggregation Propensity of Pyroglutamate A β (3-40) in Aqueous Trifluoroethanol. 2015 , 10, e0143647	21
414	Germinated Brown Rice Alters A β (1-42) Aggregation and Modulates Alzheimer's Disease-Related Genes in Differentiated Human SH-SY5Y Cells. 2015 , 2015, 153684	8
413	Twenty Years of Presenilins--Important Proteins in Health and Disease. 2015 , 21 Suppl 1, S41-8	4
412	Rarity of the Alzheimer disease-protective APP A673T variant in the United States. 2015 , 72, 209-16	31
411	Preparation and biological evaluation of conformationally constrained BACE1 inhibitors. 2015 , 23, 3260-8	15
410	Apolipoprotein D modulates amyloid pathology in APP/PS1 Alzheimer's disease mice. 2015 , 36, 1820-33	27
409	Study on the active mechanism of β -secretase inhibitors by molecular simulations. 2015 , 76, 138-48	6
408	ACAT1/SOAT1 as a therapeutic target for Alzheimer's disease. 2015 , 7, 2451-67	50
407	An Orally Available BACE1 Inhibitor That Affords Robust CNS A β Reduction without Cardiovascular Liabilities. 2015 , 6, 210-5	28
406	Cyclin-Dependent kinase 5 targeting prevents β -Amyloid aggregation involving glycogen synthase kinase 3 β and phosphatases. 2015 , 93, 1258-66	19
405	Scanning ultrasound removes amyloid- β and restores memory in an Alzheimer's disease mouse model. 2015 , 7, 278ra33	292
404	Dementia: An Overview of Risk Factors. 2015 , 187-198	4
403	Discovery of novel triazolobenzazepinones as β -secretase modulators with central A β 2 lowering in rodents and rhesus monkeys. 2015 , 25, 3488-94	13
402	Alzheimer's Disease, Drosophila melanogaster and Polyphenols. 2015 , 863, 21-53	5

401	Icariin decreases both APP and A β levels and increases neurogenesis in the brain of Tg2576 mice. 2015 , 304, 29-35	36
400	CALHM1 ion channel elicits amyloid- β clearance by insulin-degrading enzyme in cell lines and in vivo in the mouse brain. 2015 , 128, 2330-8	26
399	Mechanism of Nucleated Conformational Conversion of A β 2. 2015 , 54, 4197-207	56
398	Discovery of Small Molecules for Up-Regulating the Translation of Anti-amyloidogenic Secretase, a Disintegrin and Metalloproteinase 10 (ADAM10), by Binding to the G-Quadruplex-Forming Sequence in the 5' Untranslated Region (UTR) of Its mRNA. 2015 , 58, 3875-91	41
397	Target specific proteochemometric model development for BACE1 - protein flexibility and structural water are critical in virtual screening. 2015 , 11, 1955-72	17
396	Notch1 phenotype and clinical stage progression in non-small cell lung cancer. 2015 , 8, 9	19
395	Isolation of cholinesterase and β secretase 1 inhibiting compounds from Lycopodiella cernua. 2015 , 23, 3126-34	27
394	The role and therapeutic targeting of β and β secretase in Alzheimer's disease. 2015 , 1, FSO11	53
393	Opportunities in pharmacogenomics for the treatment of Alzheimer's disease. 2015 , 10, 229-252	18
392	Simple approach to the synthesis of novel tricyclic BACE1 inhibitor warhead through β lactam opening. 2015 , 56, 4028-4030	8
391	Parkinson's disease: From human genetics to clinical trials. 2015 , 7, 205ps20	34
390	Role of amyloid β in the induction of lipolysis and secretion of adipokines from human adipose tissue. 2015 , 4, 212-6	4
389	Targeting protein aggregation for the treatment of degenerative diseases. 2015 , 14, 759-80	255
388	1,4-Oxazine β secretase 1 (BACE1) Inhibitors: From Hit Generation to Orally Bioavailable Brain Penetrant Leads. 2015 , 58, 8216-35	58
387	Aging Mechanisms. 2015 ,	3
386	TRPC6 specifically interacts with APP to inhibit its cleavage by β secretase and reduce A β production. 2015 , 6, 8876	49
385	Alzheimer Disease. 2015 , 321-338	3
384	Increased cerebrospinal fluid calpain activity and microparticle levels in Alzheimer's disease. 2015 , 11, 465-74	20

383	Homeostatic Inflammation as Environmental-Adaptation Strategy. 2016 , 25-52	
382	Glucose Role in Treatment of Alzheimers Disease. 2016 , 5,	
381	Roles of Sodium-Calcium Exchanger Isoform-3 toward Calcium Ion Regulation in Alzheimers Disease. 2016 , 06,	2
380	Brain Lipids in the Pathophysiology and Treatment of Alzheimer Disease. 2016 ,	4
379	Beta Amyloid Peptides: Extracellular and Intracellular Mechanisms of Clearance in Alzheimer Disease. 2016 ,	4
378	The transcription factor XBP1 in memory and cognition: Implications in Alzheimer disease. 2017 , 22, 905-917	13
377	A modification-specific peptide-based immunization approach using CRM197 carrier protein:. 2017 , 22, 841-849	5
376	Proteomic Substrate Identification for Membrane Proteases in the Brain. 2016 , 9, 96	18
375	Notch1 hallmarks fibrillary depositions in sporadic Alzheimer's disease. 2016 , 4, 64	28
374	p120-catenin is necessary for neuroprotection induced by CDK5 silencing in models of Alzheimer's disease. 2016 , 138, 624-39	7
373	Neurotherapeutic Effects of Pueraria mirifica Extract in Early- and Late-Stage Cognitive Impaired Rats. 2016 , 30, 929-39	13
372	miR-186 is decreased in aged brain and suppresses BACE1 expression. 2016 , 137, 436-45	57
371	Pharmacological BACE1 and BACE2 inhibition induces hair depigmentation by inhibiting PMEL17 processing in mice. 2016 , 6, 21917	48
370	Aβ ₀ has a subtle effect on Aβ ₂ protofibril formation, but to a lesser degree than Aβ ₂ concentration, in Aβ ₂ /Aβ ₀ mixtures. 2016 , 597, 1-11	11
369	Sorting Motifs in the Cytoplasmic Tail of the Immunomodulatory E3/49K Protein of Species D Adenoviruses Modulate Cell Surface Expression and Ectodomain Shedding. 2016 , 291, 6796-812	4
368	Quantitative Assessment of the Impact of Fluorine Substitution on P-Glycoprotein (P-gp) Mediated Efflux, Permeability, Lipophilicity, and Metabolic Stability. 2016 , 59, 5284-96	39
367	Anti-amyloidogenic Heterocyclic Peptides. 2016 , 203-234	
366	Inhibiting BACE1 to reverse synaptic dysfunctions in Alzheimer's disease. 2016 , 65, 326-40	48

365	DYRK1A inhibition as potential treatment for Alzheimer's disease. 2016 , 8, 681-96	40
364	Alzheimer's therapy targeting the β -secretase enzyme BACE1: Benefits and potential limitations from the perspective of animal model studies. 2016 , 126, 183-198	31
363	Mitochondria as a therapeutic target in Alzheimer's disease. 2016 , 3, 220-227	25
362	Dual Signal Amplification Electrochemical Biosensor for Monitoring the Activity and Inhibition of the Alzheimer's Related Protease β -Secretase. 2016 , 88, 10559-10565	55
361	Design and synthesis of aminothiazole modulators of the gamma-secretase enzyme. 2016 , 26, 3928-37	14
360	Neurological dysfunctions associated with altered BACE1-dependent Neuregulin-1 signaling. 2016 , 136, 234-49	36
359	Roles of GRK Dysfunction in Alzheimer's Pathogenesis. 2016 , 215-236	
358	Prefrontal Cortical GABAergic Dysfunction Contributes to Aberrant UP-State Duration in APP Knockout Mice. 2017 , 27, 4060-4072	9
357	Discovery of S3-Truncated, C-6 Heteroaryl Substituted Aminothiazine β -Site APP Cleaving Enzyme-1 (BACE1) Inhibitors. 2016 , 59, 8593-600	10
356	Blocking the Interaction between EphB2 and ADDLs by a Small Peptide Rescues Impaired Synaptic Plasticity and Memory Deficits in a Mouse Model of Alzheimer's Disease. 2016 , 36, 11959-11973	33
355	Hydrogen sulfide ameliorates learning memory impairment in APP/PS1 transgenic mice: A novel mechanism mediated by the activation of Nrf2. 2016 , 150-151, 207-216	47
354	Neurovascular Protective Function of Endothelial Nitric Oxide - Recent Advances. 2016 , 80, 1499-503	34
353	Risk factor SORL1: from genetic association to functional validation in Alzheimer's disease. 2016 , 132, 653-665	45
352	Stepping closer to treating Alzheimer's disease patients with BACE1 inhibitor drugs. 2016 , 5, 13	64
351	Alzheimer disease: Host immune defence, amyloid- β peptide and Alzheimer disease. <i>Nature Reviews Neurology</i> , 2016 , 12, 433-4	15 18
350	Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of β -secretase inhibitors. 2016 , 7, 13042	54
349	Glycoprotein quality control-related proteins effectively inhibit fibrillation of amyloid beta 1-42. <i>Biochemical and Biophysical Research Communications</i> , 2016 , 481, 227-231	3-4 3
348	Alzheimer's disease-associated mutations increase amyloid precursor protein resistance to β -secretase cleavage and the A β 2/A β 0 ratio. 2016 , 2, 16026	45

347	Chronic Neuroinflammation Underlying Pathogenesis of Alzheimer's Disease. 2016 , 661-671	1
346	Inhibition of Wnt signaling induces amyloidogenic processing of amyloid precursor protein and the production and aggregation of Amyloid- β peptides. 2016 , 139, 1175-1191	45
345	Discovery of furo[2,3-d][1,3]thiazinamines as beta amyloid cleaving enzyme-1 (BACE1) inhibitors. 2016 , 26, 5729-5731	13
344	Therapeutic Targeting of A β 2. 2016 , 77-96	
343	β Secretase Inhibition. 2016 , 39-62	1
342	Amyloid Precursor Protein (APP) May Act as a Substrate and a Recognition Unit for CRL4CRBN and Stub1 E3 Ligases Facilitating Ubiquitination of Proteins Involved in Presynaptic Functions and Neurodegeneration. 2016 , 291, 17209-27	45
341	Post-translational regulation of the β Secretase BACE1. 2016 , 126, 170-177	17
340	Benzylpiperidine-Linked Diarylthiazoles as Potential Anti-Alzheimer's Agents: Synthesis and Biological Evaluation. 2016 , 59, 5823-46	60
339	Trehalose Alters Subcellular Trafficking and the Metabolism of the Alzheimer-associated Amyloid Precursor Protein. 2016 , 291, 10528-40	38
338	A β Degrading Proteases: Therapeutic Potential in Alzheimer Disease. 2016 , 30, 667-75	17
337	Beta-amyloid and phosphorylated tau metabolism changes in narcolepsy over time. 2016 , 20, 277-83; discussion 283	18
336	Targeting the BACE1 Active Site Flap Leads to a Potent Inhibitor That Elicits Robust Brain A β Reduction in Rodents. 2016 , 7, 271-6	27
335	Fluorescent turn-on determination of the activity of peptidases using peptide templated gold nanoclusters. 2016 , 183, 605-610	29
334	Vascular mTOR-dependent mechanisms linking the control of aging to Alzheimer's disease. 2016 , 1862, 992-1007	23
333	Fragment-Linking Approach Using (19)F NMR Spectroscopy To Obtain Highly Potent and Selective Inhibitors of β Secretase. 2016 , 59, 3732-49	42
332	Expedient Synthesis of Furo[2,3-d][1,3]thiazinamines and Pyrano[2,3-d][1,3]thiazinamines from Enones and Thiourea. 2016 , 81, 3386-90	4
331	A Novel Multifunctional Compound Camellikaempferoside B Decreases A β Production, Interferes with A β Aggregation, and Prohibits A β Mediated Neurotoxicity and Neuroinflammation. 2016 , 7, 505-18	22
330	Synthesis of pyrimido[4,5-c]azepine- and pyrimido[4,5-c]oxepine-based β Secretase modulators. 2016 , 26, 1554-1557	5

329	Interaction mechanism exploration of HEA derivatives as BACE1 inhibitors by in silico analysis. 2016 , 12, 1151-65	11
328	Melanopsin retinal ganglion cell loss and circadian dysfunction in Alzheimer's disease (Review). 2016 , 13, 3397-400	22
327	The Triggering Receptor Expressed on Myeloid Cells 2: A Molecular Link of Neuroinflammation and Neurodegenerative Diseases. 2016 , 291, 4334-41	48
326	Hydrogen Sulfide Selectively Inhibits β Secretase Activity and Decreases Mitochondrial $A\beta$ Production in Neurons from APP/PS1 Transgenic Mice. 2016 , 41, 1145-59	5
325	Glimepiride protects neurons against amyloid- β induced synapse damage. 2016 , 101, 225-36	24
324	Dysfunctional tubular endoplasmic reticulum constitutes a pathological feature of Alzheimer's disease. 2016 , 21, 1263-71	23
323	A Non-Canonical Role for β Secretase in the Retina. 2016 , 854, 333-9	1
322	MT5-MMP is a new pro-amyloidogenic proteinase that promotes amyloid pathology and cognitive decline in a transgenic mouse model of Alzheimer's disease. 2016 , 73, 217-36	68
321	Hypertension enhances $A\beta$ induced neurovascular dysfunction, promotes β Secretase activity, and leads to amyloidogenic processing of APP. 2016 , 36, 241-52	97
320	Identification of abelson tyrosine kinase inhibitors as potential therapeutics for Alzheimer's disease using multiple e-pharmacophore modeling and molecular dynamics. 2017 , 35, 883-896	4
319	The serotonergic 5-HT ₄ receptor: A unique modulator of hippocampal synaptic information processing and cognition. 2017 , 138, 145-153	44
318	Synthetic Analogues of Betulinic Acid as Potent Inhibitors of PS1/BACE1 Interaction to Reduce $A\beta$ Generation. 2017 , 35, 103-112	8
317	Management of Alzheimer's disease-An insight of the enzymatic and other novel potential targets. 2017 , 97, 700-709	19
316	Transitional B cells commit to marginal zone B cell fate by Taok3-mediated surface expression of ADAM10. 2017 , 18, 313-320	45
315	Aberrant proteolytic processing and therapeutic strategies in Alzheimer disease. 2017 , 64, 33-38	18
314	BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer's Disease Markers in Elderly Healthy Participants. <i>Journal of Alzheimers Disease</i> , 2017 , 56, 1437-1449	4-3 23
313	Flexible N-Termini of Amyloid β Protein Oligomers: A Link between Structure and Activity?. 2017 , 57, 651-664	6
312	The neurotoxicity of amyloid β protein oligomers is reversible in a primary neuron model. 2017 , 10, 4	30

311	Defining the minimum substrate and charge recognition model of gamma-secretase. 2017 , 38, 1412-1424	11
310	Alzheimer's Disease II. 2017 ,	2
309	Pharmacological tools based on imidazole scaffold proved the utility of PDE10A inhibitors for Parkinson's disease. 2017 , 9, 731-748	9
308	Insights into Formation and Structure of A β Oligomers Cross-Linked via Tyrosines. 2017 , 121, 5523-5535	12
307	Pyroglutamate-Modified Amyloid- β (42) Shows β -Helical Intermediates before Amyloid Formation. 2017 , 112, 1621-1633	13
306	Cyclin dependent kinase 5: A novel avenue for Alzheimer's disease. 2017 , 132, 28-38	29
305	β Secretase Modulators as A β 2-Lowering Pharmacological Agents to Treat Alzheimer's Disease. 2017 , 87-118	6
304	Neuronal p38 β mediates synaptic and cognitive dysfunction in an Alzheimer's mouse model by controlling β amyloid production. 2017 , 7, 45306	25
303	Protective Roles of <i>Monsonia angustifolia</i> and Its Active Compounds in Experimental Models of Alzheimer's Disease. 2017 , 65, 3133-3140	10
302	Gamma secretase inhibitors: a patent review (2013 - 2015). 2017 , 27, 851-866	10
301	Generation and Partial Characterization of Rabbit Monoclonal Antibody to Amyloid- β Peptide 1-37 (A β 7). <i>Journal of Alzheimer's Disease</i> , 2017 , 57, 135-145	4-3
300	Mitochondria are devoid of amyloid β protein (A β -producing secretases: Evidence for unlikely occurrence within mitochondria of A β generation from amyloid precursor protein. <i>Biochemical and Biophysical Research Communications</i> , 2017 , 486, 321-328	3-4 15
299	Novel Targets in Drug Discovery. 2017 , 617-632	0
298	β oscubebenol alleviates scopolamine-induced cognitive impairment by repressing acetylcholinesterase activity. 2017 , 638, 121-128	15
297	Sulfonamido-derivatives of unsubstituted carbazoles as BACE1 inhibitors. 2017 , 27, 4812-4816	7
296	Protective effects of the <i>Sophorae Fructus</i> on cognitive impairment and neuroinflammatory alteration in an A β -42-infused Alzheimer's disease mouse model. 2017 , 17, 255-268	
295	Fingolimod induces neuronal-specific gene expression with potential neuroprotective outcomes in maturing neuronal progenitor cells exposed to HIV. 2017 , 23, 808-824	10
294	Berberine modulates amyloid- β peptide generation by activating AMP-activated protein kinase. 2017 , 125, 408-417	22

293	Novel deoxyvasicinone derivatives as potent multitarget-directed ligands for the treatment of Alzheimer's disease: Design, synthesis, and biological evaluation. 2017 , 140, 118-127	19
292	Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct. 2017 , 9, 950-966	77
291	ALS-linked mutant SOD1 proteins promote A β aggregates in ALS through direct interaction with A β . <i>Biochemical and Biophysical Research Communications</i> , 2017 , 493, 697-707	3-4 5
290	Honokiol Attenuates Oligomeric Amyloid β -42-Induced Alzheimer's Disease in Mice Through Attenuating Mitochondrial Apoptosis and Inhibiting the Nuclear Factor Kappa-B Signaling Pathway. 2017 , 43, 69-81	36
289	Fully Atomistic A β 0 and A β 2 Oligomers in Water: Observation of Porelike Conformations. 2017 , 13, 4567-4583	19
288	Transthyretin neuroprotection in Alzheimer's disease is dependent on proteolysis. 2017 , 59, 10-14	40
287	RTN1 and RTN3 protein are differentially associated with senile plaques in Alzheimer's brains. 2017 , 7, 6145	17
286	Unraveling the genes implicated in Alzheimer's disease. 2017 , 7, 105-114	12
285	Stabilizing amyloid- β peptide by the N-terminus capture is capable of preventing and eliminating amyloid- β oligomers. 2017 , 53, 7673-7676	9
284	Immunostimulating peptide interfacial imprinted magnetic microspheres synthesized via Pickering emulsion polymerization. 2017 , 52, 4713-4726	12
283	Mechanisms of Neuron Loss in Alzheimer's Disease. 2017 , 47, 508-516	8
282	Restoring Soluble Amyloid Precursor Protein Functions as a Potential Treatment for Alzheimer's Disease. 2017 , 95, 973-991	49
281	Vibration-Induced-Emission (VIE) for imaging amyloid β fibrils. 2017 , 196, 395-402	19
280	Perplexity of Amyloid β Protein Oligomer Formation: Relevance to Alzheimer's Disease. 2017 , 1-50	3
279	Molecular Recognition Using Foldamers. 2017 , 511-537	3
278	Neuroprotective and Anti-Aging Potentials of Essential Oils from Aromatic and Medicinal Plants. 2017 , 9, 168	108
277	Adenosine Receptors and Memory Disorders. 2017 , 175-186	
276	A β accumulation causes MVB enlargement and is modelled by dominant negative VPS4A. <i>Molecular Neurodegeneration</i> , 2017 , 12, 61	19 39

275	Toward β -Secretase-1 Inhibitors with Improved Isoform Selectivity. 2018 , 61, 3491-3502	18
274	Effects of Bioactive Components of Green Tea on Alzheimer's Disease. 2018 , 56, 151-172	2
273	Secretase inhibitors for the treatment of Alzheimer's disease: Long road ahead. 2018 , 148, 436-452	88
272	Peripheral Activity and Central Substrates of BACE1: Therapeutic Implications for Alzheimer's Disease. 2018 , 83, 393-394	1
271	Identification of rare RTN3 variants in Alzheimer's disease in Han Chinese. 2018 , 137, 141-150	11
270	Recent advances in the neurobiology and neuropharmacology of Alzheimer's disease. 2018 , 98, 297-307	77
269	Monomeric amyloid- β reduced amyloid- β oligomer-induced synapse damage in neuronal cultures. 2018 , 111, 48-58	13
268	Proteolytic Cleavage-Mechanisms, Function, and "Omic" Approaches for a Near-Ubiquitous Posttranslational Modification. 2018 , 118, 1137-1168	99
267	RAGE mediates A β accumulation in a mouse model of Alzheimer's disease via modulation of β and β Secretase activity. 2018 , 27, 1002-1014	35
266	β Secretase ADAM10 physically interacts with β Secretase BACE1 in neurons and regulates CHL1 proteolysis. 2018 , 10, 411-422	7
265	Enzyme Immobilization on Nanoparticles: Recent Applications. 2018 , 67-80	9
264	Asparagus cochinchinensis stimulates release of nerve growth factor and abrogates oxidative stress in the Tg2576 model for Alzheimer's disease. 2018 , 18, 125	15
263	TRPC1 Null Exacerbates Memory Deficit and Apoptosis Induced by Amyloid- β <i>Journal of Alzheimer's Disease</i> , 2018 , 63, 761-772	4-3 9
262	A β 2 Protofibrils Interact with and Are Trafficked through Microglial-Derived Microvesicles. 2018 , 9, 1416-1425	16
261	BACE1 SUMOylation increases its stability and escalates the protease activity in Alzheimer's disease. 2018 , 115, 3954-3959	22
260	Neuroprotective and Antiaging Essential Oils and Lipids in Plants. 2018 , 1-18	3
259	Increased Plasma Beta-Secretase 1 May Predict Conversion to Alzheimer's Disease Dementia in Individuals With Mild Cognitive Impairment. 2018 , 83, 447-455	62
258	Homo- and Heterodimerization of Proteins in Cell Signaling: Inhibition and Drug Design. 2018 , 111, 1-59	4

257	Wnt signaling loss accelerates the appearance of neuropathological hallmarks of Alzheimer's disease in J20-APP transgenic and wild-type mice. 2018 , 144, 443-465	49
256	Short A β peptides attenuate A β 2 toxicity in vivo. 2018 , 215, 283-301	33
255	NABi, a novel sheet breaker, inhibits A β aggregation and neuronal toxicity: Therapeutic implications for Alzheimer's disease. 2018 , 1862, 71-80	2
254	mTOR in Down syndrome: Role in A β and tau neuropathology and transition to Alzheimer disease-like dementia. 2018 , 114, 94-101	59
253	Visualization of Alzheimer's Disease Related γ / β /B Secretase Ternary Complex by Bimolecular Fluorescence Complementation Based Fluorescence Resonance Energy Transfer. 2018 , 11, 431	5
252	Non-coding RNA influences in dementia. 2018 , 3, 188-194	19
251	Reduced A β secretion by human neurons under conditions of strongly increased BACE activity. 2018 , 147, 256-274	3
250	Potential value of soluble APP and APP in CSF as biomarkers of dementia disorders: Unresolved issues and perspectives. 2018 , 6, 89-93	2
249	Synthesis and Biological Profiles of 4,5-, 1,5-, and 1,2-Diaryl-1 H -imidazoles. 2018 , 83-160	
248	Dynamic micellar oligomers of amyloid beta peptides play a crucial role in their aggregation mechanisms. 2018 , 20, 20597-20614	27
247	Self-Assembly Molecular Chaperone to Concurrently Inhibit the Production and Aggregation of Amyloid β Peptide Associated with Alzheimer's Disease. 2018 , 7, 983-989	11
246	Sheet Breaker Peptide-HPYD for the Treatment of Alzheimer's Disease: Primary Studies on Behavioral Test and Transcriptional Profiling. <i>Frontiers in Pharmacology</i> , 2017 , 8, 969	5.6 10
245	Exploring the potential of marine microbes in clinical management of Alzheimer's disease: A road map for bioprospecting and identifying promising isolates. 2018 , 208, 149-160	4
244	Cosmosiin Increases ADAM10 Expression via Mechanisms Involving 5'UTR and PI3K Signaling. 2018 , 11, 198	8
243	Anti-BACE1 and Antimicrobial Activities of Steroidal Compounds Isolated from Marine <i>Urechis unicinctus</i> . 2018 , 16,	14
242	Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment. 2018 , 6, 178	91
241	An arabinogalactan from fruits of <i>Lycium barbarum</i> L. inhibits production and aggregation of A β 2018 , 195, 643-651	26
240	Computational modeling and biomarker studies of pharmacological treatment of Alzheimer's disease (Review). 2018 , 18, 639-655	10

239	Application of nanodiagnosics and nanotherapy to CNS diseases. 2018 , 13, 2341-2371		22
238	Paradoxical effects of mutant ubiquitin on A β plaque formation in an Alzheimer mouse model. 2018 , 72, 62-71		7
237	A highly sensitive fluorescent probe that quantifies transthyretin in human plasma as an early diagnostic tool of Alzheimer's disease. 2019 , 55, 10424-10427		10
236	Emerging links between cell competition and Alzheimer's disease. 2019 , 132,		9
235	QSAR Classification Models for Predicting the Activity of Inhibitors of Beta-Secretase (BACE1) Associated with Alzheimer's Disease. 2019 , 9, 9102		19
234	Quantum Yield-Engineered Biocompatible Probes Illuminate Lung Tumor Based on Viscosity Confinement-Mediated Antiaggregation. 2019 , 29, 1905124		25
233	Comparison of Methods for Differential Co-expression Analysis for Disease Biomarker Prediction. 2019 , 113, 103380		29
232	Early Stage Glycosylation Biomarkers in Alzheimer's Disease. 2019 , 6,		18
231	Development of Kinase Inactive PD173955 Analogues for Reducing Production of A β Peptides. 2019 , 10, 1430-1435		1
230	Beyond the Ligand: Extracellular and Transcellular G Protein-Coupled Receptor Complexes in Physiology and Pharmacology. 2019 , 71, 503-519		20
229	Molecular Mechanism of Binding Selectivity of Inhibitors toward BACE1 and BACE2 Revealed by Multiple Short Molecular Dynamics Simulations and Free-Energy Predictions. 2019 , 10, 4303-4318		48
228	Critical evaluation of current Alzheimer's drug discovery (2018-19) & futuristic Alzheimer drug model approach. <i>Bioorganic Chemistry</i> , 2019 , 93, 103299	5.1	18
227	Current and Emerging Pharmacological Targets for the Treatment of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019 , 72, S145-S176	4.3	19
226	Neuroprotective and Antiaging Essential Oils and Lipids in Plants. 2019 , 587-604		2
225	Simultaneous Monitoring of Amyloid- β Oligomers and Fibrils for Effectively Evaluating the Dynamic Process of A β Aggregation. 2019 , 4, 471-478		15
224	Drug Development for Alzheimer's Disease: Microglia Induced Neuroinflammation as a Target?. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	62
223	Modulating Effect of Diet on Alzheimer's Disease. 2019 , 7,		14
222	Royal jelly peptides: potential inhibitors of β -secretase in N2a/APP695swe cells. 2019 , 9, 168		10

221	A short perspective on the long road to effective treatments for Alzheimer's disease. 2019 , 176, 3636-3648	9
220	NGL-3 in the regulation of brain development, Akt/GSK3b signaling, long-term depression, and locomotive and cognitive behaviors. 2019 , 17, e2005326	9
219	Developments with multi-target drugs for Alzheimer's disease: an overview of the current discovery approaches. 2019 , 14, 879-891	29
218	In Silico Approach for Designing Potent Neuroprotective Hexapeptide. 2019 , 10, 3018-3030	5
217	Mitochondrial methionine sulfoxide reductase B2 links oxidative stress to Alzheimer's disease-like pathology. 2019 , 318, 145-156	11
216	Comprehensive review on the interaction between natural compounds and brain receptors: Benefits and toxicity. 2019 , 174, 87-115	21
215	Effect of Alpinia oxyphylla-Schisandra chinensis herb pair on inflammation and apoptosis in Alzheimer's disease mice model. 2019 , 237, 28-38	14
214	A Close Look at BACE1 Inhibitors for Alzheimer's Disease Treatment. 2019 , 33, 251-263	49
213	Pharmacological Interventions to Attenuate Alzheimer's Disease Progression: The Story So Far. 2019 , 16, 261-277	19
212	Donepezil Derivatives Targeting Amyloid- β Cascade in Alzheimer's Disease. 2019 , 16, 772-800	12
211	Mitigating Alzheimer's Disease with Natural Polyphenols: A Review. 2019 , 16, 529-543	27
210	Prospecting and Structural Insight into the Binding of Novel Plant-Derived Molecules of <i>Leea indica</i> as Inhibitors of BACE1. 2018 , 24, 3972-3979	11
209	The metalloprotease ADAMTS4 generates N-truncated A β -x species and marks oligodendrocytes as a source of amyloidogenic peptides in Alzheimer's disease. 2019 , 137, 239-257	24
208	Mechanisms of Hydrogen Sulfide against the Progression of Severe Alzheimer's Disease in Transgenic Mice at Different Ages. 2019 , 103, 50-60	28
207	Elucidating the Role of Hydroxylated Phenylalanine in the Formation and Structure of Cross-Linked A β Oligomers. 2019 , 123, 1068-1084	5
206	Sleep-wake regulation and the hallmarks of the pathogenesis of Alzheimer's disease. 2019 , 42,	17
205	Multidisciplinary approaches for targeting the secretase protein family as a therapeutic route for Alzheimer's disease. 2019 , 39, 1730-1778	11
204	Synthesis, molecular modeling and BACE-1 inhibitory study of tetrahydrobenzo[b] pyran derivatives. <i>Bioorganic Chemistry</i> , 2019 , 84, 202-210	5.1 18

203	Specific mutations in presenilin 1 cause conformational changes in β -secretase to modulate amyloid β -trimming. 2019 , 165, 37-46		7
202	Discovery of new potential triplet acting inhibitor for Alzheimer's disease via X-ray crystallography, molecular docking and molecular dynamics. 2020 , 38, 1903-1917		5
201	Coffee polyphenols prevent cognitive dysfunction and suppress amyloid β plaques in APP/PS2 transgenic mouse. 2020 , 154, 35-44		26
200	Mimicking Molecular Chaperones to Regulate Protein Folding. 2020 , 32, e1805945		28
199	The Structure and Function of β and β -Secretase as Therapeutic Target Enzymes in the Development of Alzheimer's Disease: A Review. <i>CNS and Neurological Disorders - Drug Targets</i> , 2019 , 18, 657-667	2.6	9
198	Exploring beta amyloid cleavage enzyme-1 inhibition and neuroprotective role of benzimidazole analogues as anti-alzheimer agents. 2020 , 67, 864-873		3
197	Neuroprotective effect of PPAR alpha and gamma agonists in a mouse model of amyloidogenesis through modulation of the Wnt/beta catenin pathway via targeting alpha- and beta-secretases. 2020 , 97, 109793		11
196	Classification of Metal-based Drugs According to Their Mechanisms of Action. 2020 , 6, 41-60		92
195	Glycan biomarkers for Alzheimer disease correlate with T-tau and P-tau in cerebrospinal fluid in subjective cognitive impairment. 2020 , 287, 3221-3234		17
194	Phosphorylation Signaling in APP Processing in Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2019 , 21,	6.3	22
193	Mammalian phospholipase D: Function, and therapeutics. 2020 , 78, 101018		19
192	Preparation and biological evaluation of BACE1 inhibitors: Leveraging trans-cyclopropyl moieties as ligand efficient conformational constraints. 2020 , 28, 115194		8
191	The N-glycan profile in cortex and hippocampus is altered in Alzheimer disease. 2021 , 159, 292-304		9
190	Targeting Notch Trafficking and Processing in Cancers. 2020 , 9,		4
189	Status and future directions of clinical trials in Alzheimer's disease. 2020 , 154, 3-50		13
188	The ubiquitin ligase UBE4B regulates amyloid precursor protein ubiquitination, endosomal trafficking, and amyloid β 2 generation and secretion. 2020 , 108, 103542		7
187	Photomodulating Carbon Dots for Spatiotemporal Suppression of Alzheimer's β -Amyloid Aggregation. 2020 ,		24
186	Post-Translational Modifications of Platelet-Derived Amyloid Precursor Protein by Coagulation Factor XIII-A. 2020 , 59, 4449-4455		2

185	Chronic Administration of Scopolamine Increased GSK3 β , Beta Secretase, Amyloid Beta, and Oxidative Stress in the Hippocampus of Wistar Rats. 2020 , 57, 3979-3988		7
184	An update on potential links between type 2 diabetes mellitus and Alzheimer's disease. 2020 , 47, 6347-6356		18
183	The Other Side of Alzheimer's Disease: Influence of Metabolic Disorder Features for Novel Diagnostic Biomarkers. 2020 , 10,		4
182	Revisiting the Amyloid Cascade Hypothesis: From Anti-A β Therapeutics to Auspicious New Ways for Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	42
181	Model organism development and evaluation for late-onset Alzheimer's disease: MODEL-AD. 2020 , 6, e12110		21
180	Systematic elucidation of neuron-astrocyte interaction in models of amyotrophic lateral sclerosis using multi-modal integrated bioinformatics workflow. 2020 , 11, 5579		12
179	Aluminum chloride-induced amyloid β accumulation and endoplasmic reticulum stress in rat brain are averted by melatonin. 2020 , 146, 111829		10
178	β Secretase modulators exhibit selectivity for modulation of APP cleavage but inverse β Secretase modulators do not. 2020 , 12, 61		1
177	A 3D human brain-like tissue model of herpes-induced Alzheimer's disease. 2020 , 6, eaay8828		90
176	A novel phytochemical from <i>Dipteris wallichii</i> inhibits human β Secretase 1: Implications for the treatment of Alzheimer's disease. 2020 , 143, 109839		3
175	Effects of Disulfide Bonds on Binding of Inhibitors to β Amyloid Cleaving Enzyme 1 Decoded by Multiple Replica Accelerated Molecular Dynamics Simulations. 2020 , 11, 1811-1826		33
174	Can Reduce Amyloid Beta and Reverse Cognitive Impairment and Memory Dysfunction in Alzheimer's Disease Mouse Model. 2020 , 9,		4
173	Prenatal exposure to bisphenol A alters the transcriptome-interactome profiles of genes associated with Alzheimer's disease in the offspring hippocampus. 2020 , 10, 9487		13
172	Tipping the Scales: Peptide-Dependent Dysregulation of Neural Circuit Dynamics in Alzheimer's Disease. 2020 , 107, 417-435		30
171	Is the p3 Peptide (A β 7-40, A β 7-42) Relevant to the Pathology of Alzheimer's Disease?1. <i>Journal of Alzheimer's Disease</i> , 2020 , 74, 43-53	4.3	7
170	Epigallocatechin-3-gallate Alleviates Cognitive Deficits in APP/PS1 Mice. 2020 , 40, 18-27		24
169	SERP1 is an assembly regulator of β Secretase in metabolic stress conditions. 2020 , 13,		5
168	Brain Permeable Tafamidis Amide Analogs for Stabilizing TTR and Reducing APP Cleavage. 2020 , 11, 1973-1979		3

167	Alzheimer's disease: A need for personalized therapeutic approaches. <i>Drug Development Research</i> , 2020 , 81, 141-143	5.1	3
166	Trans-Cinnamaldehyde Alleviates Amyloid-Beta Pathogenesis via the SIRT1-PGC1 β -PPAR α Pathway in 5XFAD Transgenic Mice. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	6
165	Cathepsin D regulates cerebral A β 2/40 ratios via differential degradation of A β 2 and A β 0. 2020 , 12, 80		10
164	Osirisynes G-I, New Long-Chain Highly Oxygenated Polyacetylenes from the Mayotte Marine Sponge sp. 2020 , 18,		9
163	Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain. 2020 ,		30
162	Silica Nanodepletors: Targeting and Clearing Alzheimer's β Amyloid Plaques. 2020 , 30, 1910475		15
161	Uncertainty in Pharmacology. 2020 ,		
160	Links Between Adiponectin and Dementia: From Risk Factors to Pathophysiology. 2019 , 11, 356		7
159	PI3K activation prevents A β 2-induced synapse loss and favors insoluble amyloid deposit formation. 2020 , 31, 244-260		2
158	Novel Anti-Alzheimer's Therapeutic Molecules Targeting Amyloid Precursor Protein Processing. <i>Oxidative Medicine and Cellular Longevity</i> , 2020 , 2020, 7039138	6.7	27
157	Enhancement of Amyloid β Production in the Lens Epithelium of Japanese Type 2 Diabetic Patients. 2020 , 8,		
156	Proteomics Time-Course Study of App Knock-In Mice Reveals Novel Presymptomatic A β 2-Induced Pathways to Alzheimer's Disease Pathology. <i>Journal of Alzheimers Disease</i> , 2020 , 75, 321-335	4.3	6
155	Combining Virtual Screening Protocol and In Vitro Evaluation towards the Discovery of BACE1 Inhibitors. <i>Biomolecules</i> , 2020 , 10,	5.9	8
154	Alzheimer's A β 2 and A β 0 form mixed oligomers with direct molecular interactions. <i>Biochemical and Biophysical Research Communications</i> , 2021 , 534, 292-296	3.4	4
153	NaoXinTong Capsule ameliorates memory deficit in APP/PS1 mice by regulating inflammatory cytokines. 2021 , 133, 110964		4
152	Functionalized Upconversion Nanoparticles for Disassembly of β Amyloid Aggregation with Near-Infrared Excitation. 2021 , 79, 1049		3
151	Alteration in synaptic nanoscale organization dictates amyloidogenic processing in Alzheimer's disease. 2021 , 24, 101924		6
150	Post-Translational Modifications of BACE1 in Alzheimer's Disease. 2021 ,		0

149	The biological pathways of Alzheimer disease: a review. 2021 , 8, 86-132	33
148	Cross-Linked Amyloid β Protein Oligomers: A Missing Link in Alzheimer's Disease Pathology?. 2021 , 125, 1307-1316	0
147	Plasma and cerebrospinal fluid ABeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care setting. 2021 , 2, CD010945	4
146	Recent Developments in New Therapeutic Agents against Alzheimer and Parkinson Diseases: In-Silico Approaches. 2021 , 26,	4
145	Development of a Robust High-Throughput Screening Platform for Inhibitors of the Striatal-Enriched Tyrosine Phosphatase (STEP). <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3 3
144	Nanomedicine against Alzheimer's and Parkinson's Disease. 2021 , 27, 1507-1545	3
143	Growth Factors as Axon Guidance Molecules: Lessons From Studies. 2021 , 15, 678454	1
142	A Computational Framework to Identify Cross Association Between Complex Disorders by Protein-protein Interaction Network Analysis. 2021 , 16, 433-445	2
141	Synergistic integration of metal nanoclusters and biomolecules as hybrid systems for therapeutic applications. 2021 , 11, 1175-1199	7
140	Gene Expression Profile in Different Age Groups and Its Association with Cognitive Function in Healthy Malay Adults in Malaysia. 2021 , 10,	1
139	Amyloid- β Protein Precursor Deficiency Changes Neuronal Electrical Activity and Levels of Mitochondrial Proteins in the Medial Prefrontal Cortex. <i>Journal of Alzheimer's Disease</i> , 2021 , 81, 1469-1482	4.3 1
138	Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor. 2021 , 64, 8076-8100	2
137	[Donepezil Reduces Amyloid Precursor Protein Endocytosis by Resulting from Increase in the Expression of Sorting Nexin Protein 33]. 2021 , 141, 851-856	0
136	CK1 β Derived Peptides as Novel Tools Inhibiting the Interactions between CK1 β and APP695 to Modulate the Pathogenic Metabolism of APP. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3 0
135	Binding of Inhibitors to BACE1 Affected by pH-Dependent Protonation: An Exploration from Multiple Replica Gaussian Accelerated Molecular Dynamics and MM-GBSA Calculations. 2021 , 12, 2591-2607	15
134	Investigational Drug Treatments for Triple-Negative Breast Cancer. 2021 , 11,	3
133	The Role of Non-coding RNAs in Alzheimer's Disease: From Regulated Mechanism to Therapeutic Targets and Diagnostic Biomarkers. 2021 , 13, 654978	4
132	Therapy for Alzheimer's disease: Missing targets and functional markers?. 2021 , 68, 101318	3

131	Deficiency in MT5-MMP Supports Branching of Human iPSCs-Derived Neurons and Reduces Expression of GLAST/S100 in iPSCs-Derived Astrocytes. 2021 , 10,		
130	Therapeutic Potential of Multifunctional Derivatives of Cholinesterase Inhibitors. 2021 , 19, 1323-1344		5
129	Casein Kinase 2 dependent phosphorylation of eIF4B regulates BACE1 expression in Alzheimer's disease. 2021 , 12, 769		0
128	Innate Immunity Protein IFITM3 in Alzheimer's Disease. 2021 , 40, 1351-1355		0
127	The Amyloid- β Pathway in Alzheimer's Disease. 2021 ,		63
126	Molecular Probes for Autofluorescence-Free Optical Imaging. 2021 , 121, 13086-13131		28
125	Dysregulation of the secretory pathway connects Alzheimer's disease genetics to aggregate formation. 2021 , 12, 873-884.e4		1
124	BACE1 Inhibition Increases Susceptibility to Oxidative Stress by Promoting Mitochondrial Damage. <i>Antioxidants</i> , 2021 , 10,	7.1	0
123	Industrial applications of immobilized nano-biocatalysts. 2021 , 1		5
122	Current druggable targets for therapeutic control of Alzheimer's disease. 2021 , 109, 106549		5
121	A mass spectrometric approach to study the interaction of amyloid β peptides with human α_2 -macroglobulin. 2021 , 191, 62-68		0
120	Amyloid binding and beyond: a new approach for Alzheimer's disease drug discovery targeting A β -PrP binding and downstream pathways. 2021 , 12, 3768-3785		1
119	Neuroactive venom compounds obtained from as potential leads for neurodegenerative diseases: insights on their acetylcholinesterase and beta-secretase inhibitory activities. 2021 , 27, e20210009		
118	The search for novel targets in Alzheimer's disease-The 90s redux. 2021 , 177, 123-135		1
117	Huntingtin Levels are Elevated in Hippocampal Post-Mortem Samples of Alzheimer's Disease Brain. 2020 , 17, 858-867		4
116	Alzheimer's Disease Pharmacology. 2021 ,		1
115	Local predictors of anti-A β therapy efficacy revealed by quantitative whole-brain microscopy.		
114	Identifying direct Notch transcriptional targets using the GSI-washout assay. 2014 , 1187, 247-54		3

113	Amyloid Diseases at the Molecular Level: General Overview and Focus on AL Amyloidosis. 2015 , 9-29	3
112	TGF- β in Brain Disorders. 2013 , 391-412	1
111	Altered lipid metabolic homeostasis in the pathogenesis of Alzheimer's disease. 2020 , 469-504	3
110	Design and synthesis of novel methoxypyridine-derived gamma-secretase modulators. 2020 , 28, 115734	5
109	Dimerization and Structural Stability of Amyloid Precursor Proteins Affected by the Membrane Microenvironments. 2017 , 57, 1375-1387	17
108	CHAPTER 12:Supramolecular Enzyme Assays. 2013 , 355-396	5
107	Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene-dose-sensitive AD-suppressor in human brain	1
106	Dysregulation of the secretory pathway connects Alzheimer's disease genetics to aggregate formation.	1
105	Phospho-eIF2 α level is important for determining abilities of BACE1 reduction to rescue cholinergic neurodegeneration and memory defects in 5XFAD mice. 2010 , 5, e12974	79
104	Modulation of β secretase activity by multiple enzyme-substrate interactions: implications in pathogenesis of Alzheimer's disease. 2012 , 7, e32293	13
103	FTY720/fingolimod, a sphingosine analogue, reduces amyloid- β production in neurons. 2013 , 8, e64050	59
102	Differential Inhibition of Signal Peptide Peptidase Family Members by Established β Secretase Inhibitors. 2015 , 10, e0128619	10
101	Virtual and In Vitro Screens Reveal a Potential Pharmacophore that Avoids the Fibrillization of A β -42. 2015 , 10, e0130263	9
100	Sleep and Alzheimer's Disease. 2015 , 6, 1-9	2
99	Experimental microembolism induces localized neuritic pathology in guinea pig cerebrum. 2015 , 6, 10772-85	6
98	Deletion of the β secretase subunits Aph1B/C impairs memory and worsens the deficits of knock-in mice modeling the Alzheimer-like familial Danish dementia. 2016 , 7, 11923-44	13
97	β Secretase regulates the β secretase cleavage of the Alzheimer's disease, amyloid precursor protein.	2
96	Unfolded Protein Response and PERK Kinase as a New Therapeutic Target in the Pathogenesis of Alzheimer's Disease. 2015 , 22, 3169-84	44

95	Benzimidazole-derived Compounds Designed for Different Targets of Alzheimer's Disease. 2019 , 26, 3260-3278	10
94	Potential Enzymatic Targets in Alzheimer's: A Comprehensive Review. 2019 , 20, 316-339	17
93	Synthesis and In Vitro Biological Activity Evaluation of Novel Imidazo [2,1-B][1,3,4] Thiadiazole as Anti-Alzheimer Agents. 2020 , 17, 610-617	1
92	Modulatory Effects of Autophagy on APP Processing as a Potential Treatment Target for Alzheimer's Disease. 2020 , 9,	20
91	A Review on Current Strategies and Future Perspective in Respect to Alzheimer's Disease Treatment. 2015 , 6, 1-15	4
90	Loss of canonical Wnt signaling is involved in the pathogenesis of Alzheimer's disease. 2018 , 13, 1705-1710	67
89	Accelerating Alzheimer's pathogenesis by GRK5 deficiency via cholinergic dysfunction. 2013 , 02, 148-160	5
88	Computational Analyses of Docosahexaenoic Acid (DHA, C22:6, n-3) with Alzheimer's Disease-Causing Amyloid Peptide A β ₁₋₄₂ ; Reassures Its Therapeutic Utility. 2016 , 05, 73-86	1
87	Docking and Quantitative Structure Activity Relationship studies of Acyl Guanidines as β -Secretase (BACE1) Inhibitor. 2014 , 35, 2065-2071	2
86	Methyl-CpG Binding Protein 2 in Alzheimer Dementia. 2019 , 23, S72-81	9
85	APP and APLP2 interact with the synaptic release machinery and facilitate transmitter release at hippocampal synapses. 2015 , 4, e09743	52
84	Nanomaterials for neurodegenerative diseases: Molecular mechanisms guided design and applications. 1	1
83	DHEA and Alzheimer's Disease. 2011 , 433-445	
82	Amyloid Diseases at the Molecular Level: General Overview and Focus on AL Amyloidosis. 2012 , 9-29	
81	Common Signaling Pathways Used During Development. 2013 , 503-515	1
80	Drug Treatments for Alzheimer's Disease: Hopes and Challenges. 2014 , 1173-1190	
79	Alzheimer's Disease. 2015 , 223-261	
78	Immunotherapeutic Approaches Against Amyloid- β in Drug Discovery for Alzheimer's Disease. 2015 , 395-415	

- 77 Alzheimer's Disease. **2016**, 3893-3913
- 76 A modification-specific peptide-based immunization approach using CRM197 carrier protein: Development of a selective vaccine against pyroglutamate A β peptides.
- 75 Development of a Reporter System for Monitoring of β Secretase Activity in. **2017**, 40, 73-81 2
- 74 Coffee polyphenols prevent cognitive dysfunction and suppress amyloid β plaques in APP/PS2 transgenic mouse.
- 73 Studies toward Identifying the Pharmacophore of L-755,807 for Amyloid- β Aggregation Inhibitory Activity. **2019**, 98, 1769 1
- 72 PI3K activation prevents A β 2-induced synapse loss and favors insoluble amyloid deposits formation.
- 71 From EST to structure models for functional inference of APP, BACE1, PSEN1, PSEN2 genes. **2019**, 15, 760-771
- 70 Encyclopedia of Molecular Pharmacology. **2020**, 1-6
- 69 Is It the Twilight of BACE1 Inhibitors?. **2021**, 19, 61-77 2
- 68 CHAPTER 11:Chemical Probes in Cellular Assays for Target Validation and Screening in Neurodegeneration. **2020**, 276-319
- 67 Robust Biomarkers: Methodologically Tracking Causal Processes in Alzheimer's Measurement. **2020**, 289-318 1
- 66 Statistical Model Checking in Drug Repurposing for Alzheimer's Disease. **2020**, 64-80
- 65 A dual-screening electrochemiluminescent aptasensor based on a mesoporous silica nano-sieve for specific detection of amyloid- β monomer. **2021**, 352, 131065 3
- 64 Endothelial expression of human APP leads to cerebral amyloid angiopathy in mice. 1
- 63 Inhibition of BACE1 for therapeutic use in Alzheimer's disease. **2010**, 3, 618-28 34
- 62 Bioenergetics breakdown in Alzheimer's disease: targets for new therapies. **2011**, 3, 133-9 11
- 61 Divalent cation tolerance protein binds to β Secretase and inhibits the processing of amyloid precursor protein. **2013**, 8, 991-9 2
- 60 Ultrasound attacks Alzheimer's disease?. **2015**, 3, 276

59	Cathepsin D: A Candidate Link between Amyloid β protein and Tauopathy in Alzheimer Disease. 2021 , 2, 10-15		4
58	Linagliptin Protects Human SH-SY5Y Neuroblastoma Cells against Amyloid- β Cytotoxicity via the Activation of Wnt1 and Suppression of IL-6 Release. 2021 , 25, 343-8		
57	Dimensional Changes in Lipid Rafts from Human Brain Cortex Associated to Development of Alzheimer's Disease. Predictions from an Agent-Based Mathematical Model. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	
56	Inhibition of BACE1 and amyloid β aggregation by polyketide from <i>Streptomyces</i> sp. 2021 ,		
55	Hypoxia and the Kynurenine Pathway: Implications and Therapeutic Prospects in Alzheimer's Disease. <i>Oxidative Medicine and Cellular Longevity</i> , 2021 , 2021, 5522981	6.7	3
54	Alzheimer Hastalığı Tedavisindeki Güncel Yaklaşımlar.		0
53	Par-4 in Neuronal Death and Survival in Alzheimer's Disease and Other Neurodegenerative Diseases. 2021 , 215-245		
52	Specific Mutations in Aph1 Cause β Secretase Activation.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	1
51	Dysfunction of striatal MeCP2 is associated with cognitive decline in a mouse model of Alzheimer's disease.. <i>Theranostics</i> , 2022 , 12, 1404-1418	12.1	0
50	Protection against Amyloid- β Oligomer Neurotoxicity by Small Molecules with Antioxidative Properties: Potential for the Prevention of Alzheimer's Disease Dementia.. <i>Antioxidants</i> , 2022 , 11,	7.1	0
49	The molecular mechanism, targets, and novel molecules in the treatment of Alzheimer's disease.. <i>Bioorganic Chemistry</i> , 2021 , 119, 105562	5.1	4
48	Alzheimer's Disease. 2021 , 84-89		
47	Downregulation of PIK3CB Involved in Alzheimer's Disease via Apoptosis, Axon Guidance, and FoxO Signaling Pathway.. <i>Oxidative Medicine and Cellular Longevity</i> , 2022 , 2022, 1260161	6.7	0
46	Alzheimer's Disease. 2021 , 1-22		
45	Neuroprotective role of herbal alternatives in circumventing Alzheimer's disease through multi-targeting approach - a review. <i>Egyptian Journal of Basic and Applied Sciences</i> , 2022 , 9, 91-124	1.3	
44	Spatial Training Attenuates Long-Term Alzheimer's Disease-Related Pathogenic Processes in APP/PS1 Mice.. <i>Journal of Alzheimer's Disease</i> , 2021 ,	4.3	0
43	Role of Animal Models in Alzheimer's Disease Drug Development. 2022 , 73-94		
42	Alzheimer's disease - the journey of a healthy brain into organ failure.. <i>Molecular Neurodegeneration</i> , 2022 , 17, 18	19	3

41	Secretase in Alzheimer's disease.. <i>Experimental and Molecular Medicine</i> , 2022 ,	12.8	6
40	Current Drug Targets in Alzheimer's Associated Memory Impairment: A Comprehensive Review.. <i>CNS and Neurological Disorders - Drug Targets</i> , 2022 ,	2.6	2
39	Genomics and Functional Genomics of Alzheimer's Disease.. <i>Neurotherapeutics</i> , 2021 , 1	6.4	1
38	Static and dynamic disorder in A β 0 fibrils.. <i>Biochemical and Biophysical Research Communications</i> , 2022 , 610, 107-112	3.4	
37	Image_1.TIF. 2018 ,		
36	Image_2.TIF. 2018 ,		
35	Image_3.TIF. 2018 ,		
34	Data_Sheet_1.docx. 2018 ,		
33	Disease-Modifying Therapies for Alzheimer's Disease: More Questions than Answers.. <i>Neurotherapeutics</i> , 2022 , 1	6.4	2
32	Genistein: A focus on several neurodegenerative diseases.. <i>Journal of Food Biochemistry</i> , 2022 , e14155	3.3	1
31	Constructing conformational library for amyloid- β dimers as the smallest toxic oligomers using two CHARMM force fields.. <i>Journal of Molecular Graphics and Modelling</i> , 2022 , 115, 108207	2.8	1
30	Neuroprotective Potency of Neolignans in Magnolia officinalis Cortex Against Brain Disorders. <i>Frontiers in Pharmacology</i> , 13,	5.6	
29	Non-classical glycosylation determines intracellular trafficking of APP and A β production.		
28	Design, synthesis, and biological evaluation of thienopyrimidine and thienotriazine derivatives as multitarget anti-Alzheimer agents. <i>Drug Development Research</i> ,	5.1	0
27	Multiple Mechanisms of NOTCH1 Activation in Chronic Lymphocytic Leukemia: NOTCH1 Mutations and Beyond. <i>Cancers</i> , 2022 , 14, 2997	6.6	
26	Amylin and Secretases in the Pathology and Treatment of Alzheimer's Disease. <i>Biomolecules</i> , 2022 , 12, 996	5.9	1
25	Titanium dioxide and carbon black nanoparticles disrupt neuronal homeostasis via excessive activation of cellular prion protein signaling. <i>Particle and Fibre Toxicology</i> , 2022 , 19,	8.4	0
24	Alzheimer diseases. 2023 , 313-336		0

23	Dietary Methylglyoxal Exposure Induces Alzheimer's Disease by Promoting Amyloid β Accumulation and Disrupting Autophagy in <i>Caenorhabditis elegans</i> . 2022 , 70, 10011-10021	1
22	Leukotrienes vs. Montelukast Activity, Metabolism, and Toxicity Hints for Repurposing. 2022 , 15, 1039	1
21	Based on molecular structures: Amyloid- β generation, clearance, toxicity and therapeutic strategies. 15,	2
20	Scavenging Reactive Oxygen Species Decreases Amyloid- β Levels via Activation of PI3K/Akt/GLUT1 Pathway in N2a/APP695swe Cells. 2022 , 1-14	0
19	Development of new Alzheimer's disease drug candidates using donepezil as a key model.	0
18	Alzheimer's Disease. 2022 , 4323-4344	0
17	Fats, Friends or Foes: Investigating the Role of Short- and Medium-Chain Fatty Acids in Alzheimer's Disease. 2022 , 10, 2778	0
16	Amyloidogenesis: What Do We Know So Far?. 2022 , 23, 13970	2
15	Whole-brain microscopy reveals distinct temporal and spatial efficacy of anti-A β therapies.	0
14	Molecular Mechanism of Cyanidin-3-O-Glucoside Disassembling A β Fibril In Silico. 2023 , 15, 109	0
13	Preclinical Models for Alzheimer's Disease: Past, Present, and Future Approaches. 2022 , 7, 47504-47517	0
12	<i>Withania somnifera</i> (L.) Dunal (Ashwagandha); current understanding and future prospect as a potential drug candidate. 13,	1
11	Alzheimer's disease: The Inexorable Epidemic. 2010 , 39, 505-506	0
10	Diminished α 7 nicotinic acetylcholine receptor (α 7nAChR) rescues amyloid- β induced atrial remodeling by oxi-CaMKII/MAPK/AP-1 axis-mediated mitochondrial oxidative stress. 2023 , 59, 102594	0
9	Human neurons lacking amyloid precursor protein exhibit cholesterol-associated developmental and presynaptic deficits.	0
8	Pharmacotherapy Evolution in Alzheimer's Disease: Current Framework and Relevant Directions. 2023 , 12, 131	1
7	Unraveling Presenilin 2 Functions in a Knockout Zebrafish Line to Shed Light into Alzheimer's Disease Pathogenesis. 2023 , 12, 376	0
6	Ectodomain shedding of EGFR ligands serves as an activation readout for TRP channels. 2023 , 18, e0280448	0

- 5 Specific Mutations near the Amyloid Precursor Protein Cleavage Site Increase β -Secretase Sensitivity and Modulate Amyloid- β Production. **2023**, 24, 3970 ○
- 4 Extracellular Vesicles, Cell-Penetrating Peptides and miRNAs as Future Novel Therapeutic Interventions for Parkinson's and Alzheimer's Disease. **2023**, 11, 728 ○
- 3 Human neurons lacking amyloid precursor protein exhibit cholesterol-associated developmental and presynaptic deficits. ○
- 2 β -Secretase 1 overexpression by AAV-mediated gene delivery prevents retina degeneration in a mouse model of age-related macular degeneration. **2023**, ○
- 1 Peptide aptamer targeting APP/PSyn axis reduces Alzheimer's disease pathologies in 5XFAD transgenic mouse model. **2023**, 80, ○